{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:30:56Z","timestamp":1793089856311,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T00:00:00Z","timestamp":1620000000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002642","name":"Korea University","doi-asserted-by":"crossref","award":["K1605091"],"award-info":[{"award-number":["K1605091"]}],"id":[{"id":"10.13039\/501100002642","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Korea University Sejong Future Research","award":["K1826621"],"award-info":[{"award-number":["K1826621"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Influenza viruses cause significant morbidity and mortality worldwide. Long-term or frequent use of approved anti-influenza agents has resulted in drug-resistant strains, thereby necessitating the discovery of new drugs. In this study, we found aprotinin, a serine protease inhibitor, as an anti-influenza candidate through screening of compound libraries. Aprotinin has been previously reported to show inhibitory effects on a few influenza A virus (IAV) subtypes (e.g., seasonal H1N1 and H3N2). However, because there were no reports of its inhibitory effects on the other types of influenza viruses, we investigated the inhibitory effects of aprotinin in vitro on a wide range of influenza viruses, including avian and oseltamivir-resistant influenza virus strains. Our cell-based assay showed that aprotinin had inhibitory effects on seasonal human IAVs (H1N1 and H3N2 subtypes), avian IAVs (H5N2, H6N5, and H9N2 subtypes), an oseltamivir-resistant IAV, and a currently circulating influenza B virus. We have also confirmed its activity in mice infected with a lethal dose of influenza virus, showing a significant increase in survival rate. Our findings suggest that aprotinin has the capacity to inhibit a wide range of influenza virus subtypes and should be considered for development as a therapeutic agent against influenza.<\/jats:p>","DOI":"10.1038\/s41598-021-88886-1","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T10:03:25Z","timestamp":1620036205000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Inhibitory effects of aprotinin on influenza A and B viruses in vitro and in vivo"],"prefix":"10.1038","volume":"11","author":[{"given":"Eun-Jung","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Espa\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Mu","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hyun","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiho","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Song-Kyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong-Kil","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Ki","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"88886_CR1","doi-asserted-by":"publisher","first-page":"e0169344","DOI":"10.1371\/journal.pone.0169344","volume":"12","author":"Y Young-Xu","year":"2017","unstructured":"Young-Xu, Y., van Aalst, R., Russo, E., Lee, J. K. H. & Chit, A. The annual burden of seasonal influenza in the US Veterans Affairs population. PLoS ONE 12, e0169344. https:\/\/doi.org\/10.1371\/journal.pone.0169344 (2017).","journal-title":"PLoS ONE"},{"key":"88886_CR2","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1128\/cmr.00037-06","volume":"20","author":"JSM Peiris","year":"2007","unstructured":"Peiris, J. S. M., de Jong, M. D. & Guan, Y. Avian influenza virus (H5N1): A threat to human health. Clin. Microbiol. Rev. 20, 243\u2013267. https:\/\/doi.org\/10.1128\/cmr.00037-06 (2007).","journal-title":"Clin. Microbiol. Rev."},{"key":"88886_CR3","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4142\/jvs.2017.18.S1.269","volume":"18","author":"D-H Lee","year":"2017","unstructured":"Lee, D.-H., Bertran, K., Kwon, J.-H. & Swayne, D. E. Evolution, global spread, and pathogenicity of highly pathogenic avian influenza H5Nx clade 2.3.4.4. J. Vet. Sci. 18, 269\u2013280. https:\/\/doi.org\/10.4142\/jvs.2017.18.S1.269 (2017).","journal-title":"J. Vet. Sci."},{"key":"88886_CR4","doi-asserted-by":"publisher","first-page":"e01277","DOI":"10.1128\/jvi.01277-17","volume":"91","author":"L Yang","year":"2017","unstructured":"Yang, L. et al. Genesis and spread of newly emerged highly pathogenic H7N9 avian viruses in Mainland China. J. Virol. 91, e01277-e11217. https:\/\/doi.org\/10.1128\/jvi.01277-17 (2017).","journal-title":"J. Virol."},{"key":"88886_CR5","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3390\/pathogens5040066","volume":"5","author":"PR Saunders-Hastings","year":"2016","unstructured":"Saunders-Hastings, P. R. & Krewski, D. Reviewing the history of pandemic influenza: Understanding patterns of emergence and transmission. Pathogens 5, 66. https:\/\/doi.org\/10.3390\/pathogens5040066 (2016).","journal-title":"Pathogens"},{"key":"88886_CR6","unstructured":"World Health Organization. Influenza (seasonal). https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/influenza-(seasonal) (2018)."},{"key":"88886_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","volume":"94","author":"PC Soema","year":"2015","unstructured":"Soema, P. C., Kompier, R., Amorij, J.-P. & Kersten, G. F. A. Current and next generation influenza vaccines: Formulation and production strategies. Eur. J. Pharm. Biopharm. 94, 251\u2013263. https:\/\/doi.org\/10.1016\/j.ejpb.2015.05.023 (2015).","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"88886_CR8","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1038\/nrd2175","volume":"5","author":"E De Clercq","year":"2006","unstructured":"De Clercq, E. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5, 1015\u20131025. https:\/\/doi.org\/10.1038\/nrd2175 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"88886_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/IDR.S105473","volume":"10","author":"M Hussain","year":"2017","unstructured":"Hussain, M., Galvin, H. D., Haw, T. Y., Nutsford, A. N. & Husain, M. Drug resistance in influenza A virus: The epidemiology and management. Infect. Drug Resist. 10, 121\u2013134. https:\/\/doi.org\/10.2147\/IDR.S105473 (2017).","journal-title":"Infect. Drug Resist."},{"key":"88886_CR10","first-page":"395","volume":"25","author":"H Heider","year":"1981","unstructured":"Heider, H. et al. Occurrence of amantadine- and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Virol. 25, 395\u2013400 (1981).","journal-title":"Acta Virol."},{"key":"88886_CR11","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1086\/591851","volume":"48","author":"F Hayden","year":"2009","unstructured":"Hayden, F. Developing new antiviral agents for influenza treatment: What does the future hold?. Clin. Infect. Dis. 48, S3\u2013S13. https:\/\/doi.org\/10.1086\/591851 (2009).","journal-title":"Clin. Infect. Dis."},{"key":"88886_CR12","unstructured":"Centers for Disease Control and Prevention. CDC recommends against the use of amantadine and rimantadine for the treatment or prophylaxis of influenza in the United States during the 2005\u201306 influenza season. https:\/\/stacks.cdc.gov\/view\/cdc\/25151 (2006)."},{"key":"88886_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.antiviral.2017.08.004","volume":"146","author":"LV Gubareva","year":"2017","unstructured":"Gubareva, L. V. et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2015\u20132016. Antiviral Res. 146, 12\u201320. https:\/\/doi.org\/10.1016\/j.antiviral.2017.08.004 (2017).","journal-title":"Antiviral Res."},{"key":"88886_CR14","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/irv.12534","volume":"12","author":"B Lina","year":"2018","unstructured":"Lina, B. et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza Other Respir. Viruses 12, 267\u2013278. https:\/\/doi.org\/10.1111\/irv.12534 (2018).","journal-title":"Influenza Other Respir. Viruses"},{"key":"88886_CR15","unstructured":"Centers for Disease Control and Prevention. Influenza antiviral drug resistance. https:\/\/www.cdc.gov\/flu\/treatment\/antiviralresistance.htm (2020)."},{"key":"88886_CR16","unstructured":"Public Health England. PHE guidance on the use of antiviral agents for the treatment and prophylaxis of seasonal influenza. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/833572\/PHE_guidance_antivirals_influenza_201920.pdf (2019)."},{"key":"88886_CR17","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01309780","volume":"135","author":"OP Zhirnov","year":"1994","unstructured":"Zhirnov, O. P., Golyando, P. B. & Ovcharenko, A. V. Replication of influenza B virus in chicken embryos is suppressed by exogenous aprotinin. Arch. Virol. 135, 209\u2013216. https:\/\/doi.org\/10.1007\/BF01309780 (1994).","journal-title":"Arch. Virol."},{"key":"88886_CR18","first-page":"59","volume":"2015","author":"OP Zhirnov","year":"2015","unstructured":"Zhirnov, O. P., Bokova, N. O., Isaeva, E. I., Varobieva, I. V. & Malyshev, N. A. Pathogenetic treatment of influenza patients with aerosolized form of aprotinin, a protease inhibitor. BIOpreparations Prev. Diagnosis Treat. 2015, 59\u201364 (2015).","journal-title":"BIOpreparations Prev. Diagnosis Treat."},{"key":"88886_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","volume":"92","author":"OP Zhirnov","year":"2011","unstructured":"Zhirnov, O. P., Klenk, H. D. & Wright, P. F. Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res. 92, 27\u201336. https:\/\/doi.org\/10.1016\/j.antiviral.2011.07.014 (2011).","journal-title":"Antiviral Res."},{"key":"88886_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/s0166-3542(00)00125-x","volume":"48","author":"RW Sidwell","year":"2000","unstructured":"Sidwell, R. W. & Smee, D. F. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral. Res. 48, 1\u201316. https:\/\/doi.org\/10.1016\/s0166-3542(00)00125-x (2000).","journal-title":"Antiviral. Res."},{"key":"88886_CR21","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1086\/505868","volume":"43","author":"N Kawai","year":"2006","unstructured":"Kawai, N. et al. A comparison of the effectiveness of oseltamivir for the treatment of influenza A and influenza B: A Japanese multicenter study of the 2003\u20132004 and 2004\u20132005 influenza seasons. Clin. Infect. Dis. 43, 439\u2013444. https:\/\/doi.org\/10.1086\/505868 (2006).","journal-title":"Clin. Infect. Dis."},{"key":"88886_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1620\/tjem.214.113","volume":"214","author":"M Sato","year":"2008","unstructured":"Sato, M. et al. Effectiveness of oseltamivir treatment among children with influenza A or B virus infections during four successive winters in Niigata City, Japan. Tohoku J. Exp. Med. 214, 113\u2013120. https:\/\/doi.org\/10.1620\/tjem.214.113 (2008).","journal-title":"Tohoku J. Exp. Med."},{"key":"88886_CR23","unstructured":"Zhirnov, O. P. & Ovcharenko, A. V. Pharmaceutical aerosol composition and application thereof for treatment and prophylaxis of viral diseases. US5723439A (1998)."},{"key":"88886_CR24","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1177\/095632020601700403","volume":"17","author":"DF Smee","year":"2006","unstructured":"Smee, D. F., Wong, M. H., Bailey, K. W. & Sidwell, R. W. Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir. Chem. Chemother. 17, 185\u2013192. https:\/\/doi.org\/10.1177\/095632020601700403 (2006).","journal-title":"Antivir. Chem. Chemother."},{"key":"88886_CR25","unstructured":"Fritz, H. & Jochum, M. Aprotinin and its target enzymes in vitro and in vito. in 9th Annual Meeting of the International Society for Heart Transplantation (eds D.E. Birnbaum & H.E. Hoffmeister) 42\u201351 (Schattauer, 1990)."},{"key":"88886_CR26","doi-asserted-by":"publisher","first-page":"954","DOI":"10.2165\/00003495-199549060-00008","volume":"49","author":"R Davis","year":"1995","unstructured":"Davis, R. & Whittington, R. Aprotinin. NDrugs 49, 954\u2013983. https:\/\/doi.org\/10.2165\/00003495-199549060-00008 (1995).","journal-title":"NDrugs"},{"key":"88886_CR27","doi-asserted-by":"publisher","first-page":"8682","DOI":"10.1128\/JVI.76.17.8682-8689.2002","volume":"76","author":"OP Zhirnov","year":"2002","unstructured":"Zhirnov, O. P., Ikizler, M. R. & Wright, P. F. Cleavage of influenza A virus hemagglutinin in human respiratory epithelium is cell associated and sensitive to exogenous antiproteases. J. Virol. 76, 8682. https:\/\/doi.org\/10.1128\/JVI.76.17.8682-8689.2002 (2002).","journal-title":"J. Virol."},{"key":"88886_CR28","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3851\/IMP1715","volume":"21","author":"OP Zhirnov","year":"2011","unstructured":"Zhirnov, O. P., Matrosovich, T. Y., Matrosovich, M. N. & Klenk, H.-D. Aprotinin, a protease inhibitor, suppresses proteolytic activation of pandemic H1N1v influenza virus. Antivir. Chem. Chemother. 21, 169\u2013174. https:\/\/doi.org\/10.3851\/IMP1715 (2011).","journal-title":"Antivir. Chem. Chemother."},{"key":"88886_CR29","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/0166-3542(94)90038-8","volume":"23","author":"AV Ovcharenko","year":"1994","unstructured":"Ovcharenko, A. V. & Zhirnov, O. P. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res. 23, 107\u2013118. https:\/\/doi.org\/10.1016\/0166-3542(94)90038-8 (1994).","journal-title":"Antiviral Res."},{"key":"88886_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1002\/rmv.657","volume":"20","author":"S Bertram","year":"2010","unstructured":"Bertram, S., Glowacka, I., Steffen, I., K\u00fchl, A. & P\u00f6hlmann, S. Novel insights into proteolytic cleavage of influenza virus hemagglutinin. Rev. Med. Virol. 20, 298\u2013310. https:\/\/doi.org\/10.1002\/rmv.657 (2010).","journal-title":"Rev. Med. Virol."},{"key":"88886_CR31","doi-asserted-by":"publisher","first-page":"9896","DOI":"10.1128\/JVI.01118-06","volume":"80","author":"E B\u00f6ttcher","year":"2006","unstructured":"B\u00f6ttcher, E. et al. Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 80, 9896. https:\/\/doi.org\/10.1128\/JVI.01118-06 (2006).","journal-title":"J. Virol."},{"key":"88886_CR32","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1099\/0022-1317-66-7-1633","volume":"66","author":"OP Zhirnov","year":"1985","unstructured":"Zhirnov, O. P., Ovcharenko, A. V. & Bukrinskaya, A. G. Myxovirus replication in chicken embryos can be suppressed by aprotinin due to the blockage of viral glycoprotein cleavage. J. Gen. Virol. 66, 1633\u20131638. https:\/\/doi.org\/10.1099\/0022-1317-66-7-1633 (1985).","journal-title":"J. Gen. Virol."},{"key":"88886_CR33","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/cells9112377","volume":"9","author":"D Bojkova","year":"2020","unstructured":"Bojkova, D. et al. Aprotinin inhibits SARS-CoV-2 replication. Cells 9, 2377. https:\/\/doi.org\/10.3390\/cells9112377 (2020).","journal-title":"Cells"},{"key":"88886_CR34","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/v11070620","volume":"11","author":"PT Peacock","year":"2019","unstructured":"Peacock, P. T., James, J., Sealy, E. J. & Iqbal, M. A global perspective on H9N2 avian influenza virus. Viruses 11, 620. https:\/\/doi.org\/10.3390\/v11070620 (2019).","journal-title":"Viruses"},{"key":"88886_CR35","doi-asserted-by":"publisher","first-page":"13271","DOI":"10.1128\/JVI.05038-11","volume":"85","author":"J-H Nam","year":"2011","unstructured":"Nam, J.-H. et al. Emergence of mammalian species-infectious and -pathogenic avian influenza H6N5 virus with no evidence of adaptation. J. Virol. 85, 13271. https:\/\/doi.org\/10.1128\/JVI.05038-11 (2011).","journal-title":"J. Virol."},{"key":"88886_CR36","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1007\/s00705-017-3451-9","volume":"162","author":"J-H Nam","year":"2017","unstructured":"Nam, J.-H. et al. Rapid virulence shift of an H5N2 avian influenza virus during a single passage in mice. Arch. Virol. 162, 3017\u20133024. https:\/\/doi.org\/10.1007\/s00705-017-3451-9 (2017).","journal-title":"Arch. Virol."},{"key":"88886_CR37","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.antiviral.2013.08.023","volume":"100","author":"AJ Burnham","year":"2013","unstructured":"Burnham, A. J., Baranovich, T. & Govorkova, E. A. Neuraminidase inhibitors for influenza B virus infection: Efficacy and resistance. Antiviral Res. 100, 520\u2013534. https:\/\/doi.org\/10.1016\/j.antiviral.2013.08.023 (2013).","journal-title":"Antiviral Res."},{"key":"88886_CR38","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1111\/j.1527-3466.1989.tb00521.x","volume":"7","author":"TE Emerson Jr","year":"1989","unstructured":"Emerson, T. E. Jr. Pharmacology of aprotinin and efficacy during cardiopulmonary bypass. Cardiovasc. Drug Rev. 7, 127\u2013140. https:\/\/doi.org\/10.1111\/j.1527-3466.1989.tb00521.x (1989).","journal-title":"Cardiovasc. Drug Rev."},{"key":"88886_CR39","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1099\/0022-1317-65-1-191","volume":"65","author":"OP Zhirnov","year":"1984","unstructured":"Zhirnov, O. P., Ovcharenko, A. V. & Bukrinskaya, A. G. Suppression of influenza virus replication in infected mice by protease inhibitors. J. Gen. Virol. 65, 191\u2013196. https:\/\/doi.org\/10.1099\/0022-1317-65-1-191 (1984).","journal-title":"J. Gen. Virol."},{"key":"88886_CR40","doi-asserted-by":"publisher","first-page":"EN-1287","DOI":"10.2903\/sp.efsa.2017.EN-1287","volume":"14","author":"Erasmus Medical Centre (NL)","year":"2017","unstructured":"Erasmus Medical Centre (NL) & Istituto Zooprofilattico Sperimentale delle Venezie (IT). Mechanisms and risk factors for mutation from low to highly pathogenic avian influenza virus. EFSA Support. Publ. 14, EN-1287. https:\/\/doi.org\/10.2903\/sp.efsa.2017.EN-1287 (2017).","journal-title":"EFSA Support. Publ."},{"key":"88886_CR41","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1056\/NEJMoa051379","volume":"354","author":"DT Mangano","year":"2006","unstructured":"Mangano, D. T., Tudor, I. C. & Dietzel, C. The risk associated with aprotinin in cardiac surgery. New Engl. J. Med. 354, 353\u2013365. https:\/\/doi.org\/10.1056\/NEJMoa051379 (2006).","journal-title":"New Engl. J. Med."},{"key":"88886_CR42","doi-asserted-by":"publisher","first-page":"e007570","DOI":"10.1161\/JAHA.117.007570","volume":"7","author":"U Benedetto","year":"2018","unstructured":"Benedetto, U. et al. Safety of perioperative aprotinin administration during isolated coronary artery bypass graft surgery: Insights from the ART (Arterial\u00a0Revascularization Trial). J. Am. Heart Assoc. 7, e007570. https:\/\/doi.org\/10.1161\/JAHA.117.007570 (2018).","journal-title":"J. Am. Heart Assoc."},{"key":"88886_CR43","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.athoracsur.2008.04.048","volume":"86","author":"SA Olenchock Jr","year":"2008","unstructured":"Olenchock, S. A. Jr. et al. Impact of aprotinin on adverse clinical outcomes and mortality up to 12 years in a registry of 3,337 patients. Ann. Thorac. Surg. 86, 560\u2013567. https:\/\/doi.org\/10.1016\/j.athoracsur.2008.04.048 (2008).","journal-title":"Ann. Thorac. Surg."},{"key":"88886_CR44","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.athoracsur.2007.05.015","volume":"84","author":"W Dietrich","year":"2007","unstructured":"Dietrich, W., Ebell, A., Busley, R. & Boulesteix, A.-L. Aprotinin and anaphylaxis: analysis of 12,403 exposures to aprotinin in cardiac surgery. Ann. Thorac. Surg. 84, 1144\u20131150. https:\/\/doi.org\/10.1016\/j.athoracsur.2007.05.015 (2007).","journal-title":"Ann. Thorac. Surg."},{"key":"88886_CR45","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.accpm.2017.02.001","volume":"36","author":"D Royston","year":"2017","unstructured":"Royston, D., De Hert, S., van der Linden, J., Ouattara, A. & Zacharowski, K. A special article following the relicence of aprotinin injection in Europe. Anaesth. Crit. Care Pain Med. 36, 97\u2013102. https:\/\/doi.org\/10.1016\/j.accpm.2017.02.001 (2017).","journal-title":"Anaesth. Crit. Care Pain Med."},{"key":"88886_CR46","doi-asserted-by":"publisher","first-page":"I-127","DOI":"10.1161\/CIRCULATIONAHA.106.681395","volume":"116","author":"P Furnary Anthony","year":"2007","unstructured":"Furnary Anthony, P., Wu, Y., Hiratzka Loren, F., Grunkemeier Gary, L. & Page, U. S. 3rd. Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116, I-127-I\u2013133. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.681395 (2007).","journal-title":"Circulation"},{"key":"88886_CR47","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.jtcvs.2012.07.018","volume":"145","author":"N Howell","year":"2013","unstructured":"Howell, N., Senanayake, E., Freemantle, N. & Pagano, D. Putting the record straight on aprotinin as safe and effective: Results from a mixed treatment meta-analysis of trials of aprotinin. J. Thorac. Cardiovasc. Surg. 145, 234\u2013240. https:\/\/doi.org\/10.1016\/j.jtcvs.2012.07.018 (2013).","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"88886_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1097\/EJA.0000000000000284","volume":"32","author":"European Society of Anaesthesiology task force reports on place of aprotinin in clinical anaesthesia","year":"2015","unstructured":"European Society of Anaesthesiology task force reports on place of aprotinin in clinical anaesthesia. Aprotinin: Is it time to reconsider?. Eur. J. Anaesthesiol. 32, 591\u2013595. https:\/\/doi.org\/10.1097\/EJA.0000000000000284 (2015).","journal-title":"Eur. J. Anaesthesiol."},{"key":"88886_CR49","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a118408 (1938).","journal-title":"Am. J. Epidemiol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88886-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88886-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88886-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T07:38:45Z","timestamp":1670053125000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-88886-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["88886"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-88886-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,3]]},"assertion":[{"value":"18 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9427"}}